Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Sep 04, 2018 12:21pm
136 Views
Post# 28559402

RE:RBC report

RE:RBC report
Thanks SPCEO. 

As per usual, the market shoots first and answers questions later.

Any feedback from management on this report?

Surely, they have to be disappointed.

bfw


SPCEO1 wrote: I have had a quick read of the RBC report. He basically talked to Key Opinion Leaders (KOL's) and used their feedback to come up with a very low expectation of patients for Trogarzo. Interestingly, those long timers here will remember that when the Trogarzo deal was first signed, the expectation was that its sales would amount to about as much as Egrifta's. This was based on TH talking to KOL's as well. Once they did their market research, however, they concluded the market was much larger. Unfortunately, it will take a while and results that don't comport withhis low view of the number of patients.for the analyst to change his forecasts higher. 

Basically, it looks to me that he concluded that about 75-80% of the MDR patients are effectively homeless people who will not come in on a regular basis to get an IV. Therefore, that large percentage of the 20-25,000 MDR patients will never recieve treatment. If you are looking for a quck summary of why he comes up with low number of patients, that explains much of it. 

Now, the company needs to prove him worng, but that will take some time to accomplish. 


Bullboard Posts